Immunotherapy is set to become the default treatment for the vast majority of lung cancer patients after a clinical trial from drugmaker Merck showed that adding its novel medicine to chemotherapy boosted survival.
制药公司默克(Merck)的一项临床试验显示，其研发的新药物联合化疗会提高肺癌患者存活率，免疫疗法将成为绝大多数肺癌患者的默认疗法。
您已阅读9%（280字），剩余91%（2918字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。